Humoral fluid phase pattern recognition molecules (PRMs) are a key component of the activation and regulation of innate immunity. Humoral PRMs are diverse. We focused on the long pentraxin PTX3 as a paradigmatic example of fluid phase PRMs. PTX3 acts as a functional ancestor of antibodies and plays a non-redundant role in resistance against selected microbes in mouse and man and in the regulation of inflammation. This molecule interacts with complement components, thus modulating complement activation. In particular, PTX3 regulates complement-driven macrophage-mediated tumor progression, acting as an extrinsic oncosuppressor in preclinical models and selected human tumors. Evidence collected over the years suggests that PTX3 is a biomarker and potential therapeutic agent in humans, and pave the way to translation of this molecule into the clinic.

Pentraxins in the activation and regulation of innate immunity / K. Daigo, A. Inforzato, I. Barajon, C. Garlanda, B. Bottazzi, S. Meri, A. Mantovani. - In: IMMUNOLOGICAL REVIEWS. - ISSN 0105-2896. - 274:1(2016 Nov), pp. 202-217. [10.1111/imr.12476]

Pentraxins in the activation and regulation of innate immunity

A. Inforzato
Secondo
;
2016

Abstract

Humoral fluid phase pattern recognition molecules (PRMs) are a key component of the activation and regulation of innate immunity. Humoral PRMs are diverse. We focused on the long pentraxin PTX3 as a paradigmatic example of fluid phase PRMs. PTX3 acts as a functional ancestor of antibodies and plays a non-redundant role in resistance against selected microbes in mouse and man and in the regulation of inflammation. This molecule interacts with complement components, thus modulating complement activation. In particular, PTX3 regulates complement-driven macrophage-mediated tumor progression, acting as an extrinsic oncosuppressor in preclinical models and selected human tumors. Evidence collected over the years suggests that PTX3 is a biomarker and potential therapeutic agent in humans, and pave the way to translation of this molecule into the clinic.
cancer-related inflammation; complement activation; inflammation; opsonization; pentraxins; PTX3; Immunology and Allergy; Immunology
Settore BIO/10 - Biochimica
Settore MED/04 - Patologia Generale
nov-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
Daigo_et_al-2016_Immunological_Reviews.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 783.93 kB
Formato Adobe PDF
783.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/455299
Citazioni
  • ???jsp.display-item.citation.pmc??? 36
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 77
social impact